Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gadoteridol
Drug ID BADD_D00993
Description Gadoteridol provides contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies. n MRI, visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoteridol shortens the T1 relaxation time in tissues where it accumulates. Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoteridol in lesions such as neoplasms, abscesses, and subacute infarcts.
Indications and Usage Gadoteridol is an MRI contrast agent used for contrast enhancement of the brain, spine and surrounding tissues resulting in improved visualization (compared with unenhanced MRI) of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood brain barrier. Gadoteridol can also be used for whole body contrast enhanced MRI including the head, neck, liver, breast, musculoskeletal system and soft tissue pathologies.
Marketing Status approved; investigational
ATC Code V08CA04
DrugBank ID DB00597
KEGG ID D01137
MeSH ID C062402
PubChem ID 60714
TTD Drug ID D0M1PL
NDC Product Code 0270-1111; 57876-111; 73435-009
UNII 0199MV609F
Synonyms gadoteridol | Gd-HP-DO3A | gadolinium 1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane | GdHPDO3A | Gd-hydroxypropyl-D03A | gadolinium 1,4,7-tris(carboxymethyl)-10-(2'-hydroxypropyl)-1,4,7,10-tetraazacyclododecane | gadolinium HP-DO3A | Gd-HPDO3A | Gd(DO3A) | Gd-HP-D03A | Prohance | SQ 32692 | SQ 32,692 | SQ-32692
Chemical Information
Molecular Formula C17H29GdN4O7
CAS Registry Number 120066-54-8
SMILES CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperhidrosis08.01.03.028; 23.02.03.0040.071845%
Hypersensitivity10.01.03.0030.105989%
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023; 23.03.03.0810.010670%-
Hypotension24.06.03.0020.061886%
Injection site erythema08.02.03.001; 12.07.03.001; 23.03.06.015---
Injection site pain08.02.03.010; 12.07.03.011---
Injection site reaction08.02.03.014; 12.07.03.015--
Lacrimation increased06.08.02.004--
Laryngeal oedema10.01.05.003; 22.04.02.001; 23.04.01.0050.014227%
Laryngospasm22.04.02.002--
Lip oedema07.05.04.004; 10.01.05.004; 23.04.01.006---
Lip swelling07.05.04.005; 10.01.05.005; 23.04.01.0070.007113%-
Loss of consciousness17.02.04.0040.042680%-
Malaise08.01.01.0030.032010%
Muscle rigidity15.05.04.001; 17.05.02.0050.007113%-
Muscle twitching15.05.03.0050.014227%-
Muscular weakness15.05.06.001; 17.05.03.0050.015649%
Myalgia15.05.02.0010.022763%
Nasal congestion22.04.04.0010.010670%
Nausea07.01.07.0010.291649%
Nodal rhythm02.03.03.021---
Ocular hyperaemia06.04.05.0040.039835%-
Oedema08.01.07.006; 14.05.06.010---
Pain08.01.08.004--
Pallor08.01.03.032; 23.03.03.031; 24.03.04.0010.074691%-
Palpitations02.11.04.0120.026320%
Paraesthesia17.02.06.005; 23.03.03.0940.032010%
Paralysis17.01.04.004---
Pneumothorax22.05.02.0030.007113%
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages